Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression
- 25 April 2018
- journal article
- research article
- Published by Physicians Postgraduate Press, Inc in British Journal of Psychology
- Vol. 79 (2), 24-32
- https://doi.org/10.4088/jcp.17m11725
Abstract
Background: Treatment-resistant depression (TRD) poses a substantial burden to health care payers including employers, costing an estimated $29 billion-$48 billion yearly in the United States. Furthermore, variation of burden across increasing levels of resistance and the potential impact of TRD on employment status remain largely unexplored. Objective: To evaluate health care resource utilization (HRU) and costs, work loss, indirect costs, and employment status change in TRD. Methods: A claims-based algorithm identified adults with TRD from a US claims database of privately insured employees and dependents (January 2010-March 2015). TRD patients were matched 1:1 on demographics to patients with major depressive disorder (MDD) (non-TRD MDD) and without MDD (non-MDD), who were identified using ICD-9-CM codes. Costs, HRU, and employment status change were compared over 2 years following the first antidepressant (randomly imputed date for non-MDD), adjusting for baseline comorbidity index and costs. Results: TRD patients (N = 6,411) had more HRU than either matched control cohort, translating into higher per patient per year (PPPY) health care costs: $6,709 and $9,917 more than nonTRD MDD and non-MDD patients, respectively (P < .001 for both). TRD patients with work loss data (N = 1,908) had 35.8 work loss days PPPY (1.7 and 6.2 times the work loss rate in non-TRD MDD and non-MDD patients, respectively). Work loss-related costs in TRD patients were $1,811 higher than non-TRD MDD and $3,460 higher than in non-MDD patients (P < .001). TRD patients had 1.3-1.4 times the rate of employment status change versus control cohorts (all P < .05). Conclusions: TRD, even compared to MDD, poses a significant direct and indirect cost burden to US employers and may be associated with higher rates of employment status change.Keywords
This publication has 13 references indexed in Scilit:
- The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010PLOS ONE, 2013
- The Economic Burden of Treatment-Resistant DepressionClinical Therapeutics, 2013
- The Epidemiology of Depression Across CulturesAnnual Review of Public Health, 2013
- The economic impact of depression: Resistance or severity?European Neuropsychopharmacology, 2010
- Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorderCurrent Medical Research and Opinion, 2010
- Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performanceDepression and Anxiety, 2009
- Depression and Retirement in Late Middle‐Aged U.S. WorkersHealth Services Research, 2007
- Cost-of-illness studies of depression: A systematic reviewJournal of Affective Disorders, 2007
- The Epidemiology of Major Depressive DisorderJAMA, 2003
- Cost of depression: current assessment and future directionsExpert Review of Pharmacoeconomics & Outcomes Research, 2001